Small molecule · Antagonist of L-type calcium channel · developed by Milestone Pharms Usa
Etripamil is an L-type calcium channel antagonist administered as a nasal spray. It modulates calcium influx across AV nodal cells and smooth muscle cells, interrupting reentry at the AV node to restore sinus rhythm in patients with paroxysmal supraventricular tachycardia.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 8, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06716021 | Phase 3 | Atrial Fibrillation | Recruiting | MIST |
| NCT04952610 | Phase 3 | Paroxysmal Supraventricular Tachycardia | Completed | MIST |
| NCT04072835 | Phase 3 | Paroxysmal Supraventricular Tachycardia | Completed | MIST |
| NCT03635996 | Phase 3 | Paroxysmal Supraventricular Tachycardia | Terminated | MEDP |
| NCT03464019 | Phase 3 | Paroxysmal Supraventricular Tachycardia | Terminated | MEDP |
| NCT05511870 | Phase 1 | Healthy Chinese Subjects | Completed | MIST |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Atrial FibrillationHealthy Chinese SubjectsParoxysmal Supraventricular Tachycardia
Updated Oct 3, 2026. Something wrong or missing? Report it on the MIST page.
See MIST's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MIST catalysts and pipeline →